China is tightening aspects of clinical trial oversight for investigator-initiated trials, even as U.S. stakeholders look to China’s earlier speed as a model. A STAT+ report says the system that allowed trials to start without formal sign-off from China’s National Medical Products Administration (NMPA) is now facing heightened scrutiny. The article frames ITTs as a contributor to China’s rapid biomedical translation, broader physician involvement in drug development, and billions in sales from newly approved medicines. But it also points to concerns emerging around patient safety, transparency, and intellectual property practices. The report suggests the U.S. clinical trial and regulatory model is under pressure to modernize, while China’s modifications indicate that the speed engine may be shifting from permissive initiation toward more structured review.